|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Grant Life Sciences (GLIF.OB) Concludes Licensing Of Point-Of-Care -POC- Diagnostic Platform From AccuDx Corp.
10/19/2005 5:13:00 PM
Grant Life Sciences (OTC Bulletin Board: GLIF) announced today that it has signed a licensing agreement with AccuDx Corp., a biotechnology company based in La Jolla, Calif., founded by Ravi Pottahil, Ph.D., one of the world's leading authorities in the field of HIV/AIDS diagnostics and therapeutics.
Under the agreement, Grant Life Sciences now controls the exclusive rights to AccuDx's rapid tests for HIV-1, HIV-2, and Dengue Fever, as well as AccuDx's proprietary colloidal gold reagent. In addition, Grant Life Sciences has the right to manufacture these products in AccuDx's `maquiladora'-modeled contract manufacturing facility in Tijuana, Mexico. This facility is registered with the FDA and is ISO 9002-certified. Financial terms of the agreement were not disclosed.
|
|
|
|
|
|
|
|
|
|
|